Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
PolyPid Ltd. (PYPD)
NASDAQ:PYPD
PolyPid (PYPD) Stock Price & Analysis
140 Followers
PYPD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.38 - $11.97
Previous Close$3.43
Volume1.48K
Average Volume (3M)5.43K
Market Cap
$5.67M
Enterprise Value$12.14M
Total Cash (Recent Filing)$5.31M
Total Debt (Recent Filing)$11.78M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Aug 07, 2024EPS Estimate
-$1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.74
Shares Outstanding1,653,559
10 Day Avg. Volume9,102
30 Day Avg. Volume5,427
Standard Deviation0.21
R-Squared0.10
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)-3.36
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.60
Forecast
1Y Price Target
$12.33Price Target Upside259.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
PolyPid News
PremiumCompany Announcements
PolyPid Ends Equity Sales Agreement, No Penalties Incurred
PremiumCompany Announcements
PolyPid Revamps Share Option Plan for Stakeholders
PremiumCompany Announcements
PolyPid Advances Trial for Infection Prevention
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe SHIELD II trial is making significant strides, with over 200 subjects enrolled and an interim analysis on the horizon, signaling a promising development in the fight against surgical site infections.
Financial StabilityPolyPid's financial discipline is evidenced by a narrower than expected net loss, combined with a solid cash position, providing stability as it approaches key trial milestones.
Product EfficacyD-PLEX, in combination with standard-of-care, has shown a 54% reduction in surgical site infections and mortality, underscoring its potential to significantly improve patient outcomes.
Bears Say
Drug ApprovalRisks include failure of the Phase 3 SHIELD II confirmatory trial and failure to obtain U.S. approval of D-PLEX.
EarningsFor 4Q23, the company recorded a net loss of $3.90 per share—wider than the forecast.
FinancingRecent PIPE financing extends cash runway into 3Q24—lowering price target based on equity dilution.
---
Ownership Overview
0.00%
Insiders
0.03% Mutual Funds
25.21% Other Institutional Investors
74.77% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PYPD FAQ
What was PolyPid Ltd.’s price range in the past 12 months?
PolyPid Ltd. lowest stock price was $3.38 and its highest was $11.97 in the past 12 months.
What is PolyPid Ltd.’s market cap?
Currently, no data Available
When is PolyPid Ltd.’s upcoming earnings report date?
PolyPid Ltd.’s upcoming earnings report date is Aug 07, 2024 which is in 16 days.
How were PolyPid Ltd.’s earnings last quarter?
PolyPid Ltd. released its earnings results on May 08, 2024. The company reported -$1.37 earnings per share for the quarter, beating the consensus estimate of -$1.413 by $0.043.
Is PolyPid Ltd. overvalued?
According to Wall Street analysts PolyPid Ltd.’s price is currently Undervalued.
Does PolyPid Ltd. pay dividends?
PolyPid Ltd. does not currently pay dividends.
What is PolyPid Ltd.’s EPS estimate?
PolyPid Ltd.’s EPS estimate is -$1.3.
How many shares outstanding does PolyPid Ltd. have?
PolyPid Ltd. has 1,653,559 shares outstanding.
What happened to PolyPid Ltd.’s price movement after its last earnings report?
PolyPid Ltd. reported an EPS of -$1.37 in its last earnings report, beating expectations of -$1.413. Following the earnings report the stock price went down -11.317%.
Which hedge fund is a major shareholder of PolyPid Ltd.?
Among the largest hedge funds holding PolyPid Ltd.’s share is ARK Investment Management LLC. It holds PolyPid Ltd.’s shares valued at N/A.
---
PolyPid Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.33 (259.48% Upside)
$12.33 (259.48% Upside)
Hedge Fund Trend
Decreased
By 1.1K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.60%
12-Months-Change
Fundamentals
Return on Equity
-261.37%
Trailing 12-Months
Asset Growth
-19.88%
Trailing 12-Months
Company Description
PolyPid Ltd.
PolyPid Ltd was incorporated under the laws of Israel and commenced its operations on February 28, 2008. The Company is a clinical stage specialty pharmaceutical company engaged in research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the Company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, BonyPid-1000, BonyPid-500, PLEX, and D-PLEX are trademarks of the Company. The Company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.
---
PYPD Stock 12 Month Forecast
Average Price Target
$12.33
▲(259.48% Upside)
Technical Analysis
Best Analysts Covering PYPD
1 Year
1 Year Success Rate
0/23 ratings generated profit
1 Year Average Return
-66.56%
reiterated a buy rating last month
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -66.56% per trade.
---